Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD) trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been systematically assessed. We proposed to assess placebo responses in two categories of MDD trials: pharmacological (antidepressant drugs) and non-pharmacological (device- rTMS) trials. METHODOLOGY/PRINCIPAL FINDINGS: We performed a systematic review and meta-analysis of the literature from April 2002 to April 2008, searching MEDLINE, Cochrane, Scielo and CRISP electronic databases and reference lists from retrieved studies and conference abstracts. We used the keywords placebo and depression and escitalopram for pharmacological studies; and transcranial magnetic stimulation and depression and sham for non-pharmacological studies. All randomized, double-blinded, placebo-controlled, parallel articles on major depressive disorder were included. Forty-one studies met our inclusion criteria - 29 in the rTMS arm and 12 in the escitalopram arm. We extracted the mean and standard values of depression scores in the placebo group of each study. Then, we calculated the pooled effect size for escitalopram and rTMS arm separately, using Cohen's d as the measure of effect size. We found that placebo response are large for both escitalopram (Cohen's d - random-effects model - 1.48; 95%C.I. 1.26 to 1.6) and rTMS studies (0.82; 95%C.I. 0.63 to 1). Exploratory analyses show that sham response is associated with refractoriness and with the use of rTMS as an add-on therapy, but not with age, gender and sham method utilized. CONCLUSIONS/SIGNIFICANCE: We confirmed that placebo response in MDD is large regardless of the intervention and is associated with depression refractoriness and treatment combination (add-on rTMS studies). The magnitude of the placebo response seems to be related with study population and study design rather than the intervention itself.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“methodological issues, including aspects of study design and conduct (i.e., issues with identifying appropriate patients, large multi-site trials, multiple raters) that have been previously proposed as possible reasons for negative clinical trials in MDD”
From A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD (2015) · cites this paper as Brunoni et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, to our knowledge, our review provides the first comprehensive insight into the control group response in non-pharmacological interventions in depression.”
From Challenges establishing the efficacy of exercise as an antidepressant treatment: a systematic review and meta-analysis of control group responses in exercise randomised controlled trials (2016) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The authors [19] found a similar increased control group improvement (SMD=-0.8) to ourselves”
The cited source says what the claim attributes to it.
In the citing paper
“response rates to placebo can be high in clinical trials of MDD (Brunoni et al, 2009;Walsh et al, 2002)”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Brunoni et al, 2009
In the citing paper
“A large placebo response has also been reported in non-pharmacological interventions for depression, with a recent meta-analysis demonstrating an effect size of 0.82 (95% CI 0.63 to 1) for control group responses in trials of repetitive transcranial magnetic stimulation [19].”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“We also performed sensitivity analysis, cumulative regression and assessed publication bias using Beggmodified funnel plot and Egger test [24] for each analysis.”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“Unsuccessful blinding biases the results as expectation effects and intervention confidence will be lost [45,46,47,48], therefore diminishing placebo response.”
BackgroundMoher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560 · cited 1×
“Unsuccessful blinding biases the results as expectation effects and intervention confidence will be lost [45,46,47,48], therefore diminishing placebo response.”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442 · cited 4×
“The main finding of our study is that both placebo interventions are associated with a large effect size in major depressive disorder, which is in line with previous studies: Walsh et al. [1] reviewed 75 depression trials and concluded that placebo response is substantial and increasing over years; Stein et al. [35] i…”
BackgroundInfluentialSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 1×
“However, our study is in line with previous meta-analyses that showed similar placebo responses in major depression studies [1,52], assessed a significant number (1714) of patients and included unpublished studies; therefore this hypothesis is less likely.”
ResultPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 4×
“7% [1] and that drug-placebo differences might be relatively small in patients with MDD due to the large placebo response [2].”
BackgroundResultInfluentialSham device v inert pill: randomised controlled trial of two placebo treatments
Kaptchuk, T. J., Stason, W. B., Davis, R. B., Legedza, A. R. T., Schnyer, R. N., Kerr, C. E., Stone, D. A., Nam, B. H., Kirsch, I., & Goldman, R. H. (2006) · BMJ · doi:10.1136/bmj.38726.603310.55 · Cited by 532 · cited 2×
“inert pill trial [37] and in a metaanalysis comparing subcutaneous placebo with oral placebo from acute migraine [38].”
BackgroundSelf-citationDo medical devices have enhanced placebo effects?
Kaptchuk, T. J., Goldman, P., Stone, D. A., & Stason, W. B. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00206-7 · Cited by 463 · cited 2×
“placebo response than placebo pills [8,36].”
BackgroundSelf-citationFitzgerald, P. B., Brown, T. L., Marston, N. A. U., Daskalakis, Z. J., de Castella, A., & Kulkarni, J. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.1002 · Cited by 458 · cited 1×
“For rTMS studies that used MADRS scores as the primary outcome, we used the values of HDRS scores reported in secondary outcomes when this was possible [26,28,29,30,31]; in four studies this was not possible [20,32,33,34] and therefore we imputed missing HDRS scores regressing for other variables.”
Method
Cited by
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
Brunoni, A. R., Valiengo, L., Baccaro, A., Zanão, T. A., de Oliveira, J. F., Goulart, A., Boggio, P. S., Lotufo, P. A., Benseñor, I. M., & Fregni, F. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.32 · Cited by 601
Self-citationAnimal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
“Due to high placebo response rates (Brunoni et al. 2009) and side effect concerns, monoamine-based agents still constitute a significant proportion of “new” antidepressants being tested in clinical trials (Mathew et al. 2008).”
BackgroundSmith, C. A., Hay, P. P., & MacPherson, H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004046.pub3 · Cited by 323
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
Richard, I. H., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J., Serrano Ramos, C., Brodsky, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182516244 · Cited by 338
Metadata
- Authors
- Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Corresponding author
- Fregni, Felipe
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-18
- Volume
- 4
- Issue
- 3
- Pages
- e4824
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2653635
- OpenAlex
- W2057880023
- Cited by
- 173
- References
- 74
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 6 · 2016: 6 · 2015: 15 · 2014: 10 · 2013: 16 · 2012: 13
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Center for Complementary and Integrative Health (K24AT004095)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- placebo response, major depressive disorder, repetitive transcranial magnetic stimulation, escitalopram, antidepressants, treatment-resistant depression, adjunctive therapy
- MeSH terms
- Major Depressive Disorder, Double-Blind Method, Humans, Placebos, Citalopram, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0004824
- The paper
- Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009). Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0004824
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.